SELLAS Life Sciences Group, Inc. (SLS) Stock

SELLAS Life Sciences Group, Inc. (SLS) is a Healthcare stock trading at $8.07 (as of 2026-06-18), with a market capitalization of $1.73B and a trailing P/E of -40.5. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

SELLAS Life Sciences Group, Inc. is a biopharmaceutical company developing cancer immunotherapies, including galinpepimut-S (GPS) targeting Wilms tumor 1 and nelipepimut-S targeting HER2. Its programs are evaluated in clinical trials in areas such as acute myeloid leukemia, ovarian cancer, and early-stage breast cancer, including a collaboration with Merck to assess GPS with pembrolizumab across multiple indications.

Valuation — source: SEC EDGAR (first-party)
Price	$8.07
Market Cap	$1.73B
P/E Ratio	-40.5
Price / Book	16.12
DCF Value (model)	$-2.29
DCF Upside vs Price	-128.4%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$0.00
Return on Equity	-27.4%
Current Ratio	17.22
Revenue Growth (YoY)	-100.0%
Revenue Growth (3Y)	-100.0%
EPS Growth (YoY)	-37.1%

Valuation vs Sector & Industry
Stock P/E	-40.5
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-293.8%
vs Industry	-337.9%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Insider Buys (12mo)	1
Top Institutional Holder	BlackRock, Inc. ($51.60M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Angelos Stergiou
Employees	15
Country	US
IPO Date	2008-03-12

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.